# A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 60 Years and Above

> **NCT04841577** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 976 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **BIOLOGICAL:** RSVPreF3 OA investigational vaccine
- **BIOLOGICAL:** FLU-QIV

## Key facts

- **NCT ID:** NCT04841577
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-27
- **Primary completion:** 2021-09-22
- **Final completion:** 2022-02-08
- **Target enrollment:** 976 (ACTUAL)
- **Last updated:** 2024-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04841577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04841577, "A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 60 Years and Above". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04841577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*